Advanced search
Publication Cover
Journal of Blood Medicine Volume 12, 2021 - Issue
Submit an article Journal homepage
188
Views
4
CrossRef citations to date
0
Altmetric
Review

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma

Karun Neupane1 Department of Internal Medicine, Manipal College of Medical Sciences, Pokhara, Gandaki, NepalCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7950-5287
ORCID Icon,
Ahsan Wahab2 Department of Internal Medicine, Baptist Medical Center South/University of Alabama at Birmingham, Montgomery, AL, USA
,
Adeel Masood3 Department of Internal Medicine, Tidal Health Peninsula Regional, Salisbury, MD, USAORCID Iconhttps://orcid.org/0000-0001-7085-777X
ORCID Icon,
Tehniat Faraz4 Department of Biochemistry, Dow University of Health Sciences, Karachi, Sindh, PakistanORCID Iconhttps://orcid.org/0000-0002-8240-6973
ORCID Icon,
Saman Bahram5 Department of Internal Medicine, Dow University of Health Sciences, Karachi, Sindh, Pakistan
,
Hamid Ehsan6 Department of Biomedic Sciences/Biohazardous Threat Agents & Emerging Infectious Diseases, Georgetown University, Washington, DC, USAORCID Iconhttps://orcid.org/0000-0002-4607-3171
ORCID Icon,
Abdul Hannan7 Department of Hematology/Oncology, Simmons Cancer Institute at Southern Illinois University School of Medicine, Springfield, IL, USA
&
Faiz Anwer8 Department of Hematology/Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
 show all
Pages 529-550 | Published online: 01 Jul 2021

Figures & data

Figure 1 Mechanism of action of Selinexor and Belamaf.

Figure 1 Mechanism of action of Selinexor and Belamaf.

Table 1 Toxicity Profile of Selinexor

Table 2 Adverse Events Leading to Modifications in Treatment Plan in Selinexor Studies

Table 3 Toxicity Profile of Belantamab

Table 4 Management of Ocular Toxicity of Belamaf

Table 5 Management of Toxicities of Selinexor and Belamaf

Table 6 Ongoing Clinical Studies for Selinexor and Belantamab (Source: Clinicaltrials.gov)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.